Personalized and Precision Medicine Journal

Abstract Background and Objectives:
The coronavirus first appeared in Wuhan, China, in late November 2019, and has since spread to more than one hundred countries. COVID-19 has been declared by the World Health Organization as a Public Health Emergency of International Interest. This has been the result of a virus now having reached pandemic proportions and there not being an effective vaccine or antiviral treatment. In this article, we aim to highlight each current drug being tested for potential effectiveness on this disease.
Methodology: The research is a descriptive review conducted by a search in reputable scientific databases, including Scopus, Google Scholar, and PubMed, utilizing the phrases virus, coronavirus, COVID-19, SARS-CoV-2, and treatment. The latest expertise:given that the development and efficacy of antiviral drugs require substantial time, monotherapy for other diseases may represent the most efficient therapeutic option for a certain condition. Pharmaceuticals with broad-spectrum efficacy, including Bevacizumab, Methylprednisolone, Fingolimod, fluoxetine, Ritonavir, chloroquine Fesnate, remdesivir, and Favipiravir, are currently under investigation as prospective candidates in various clinical trials.
Conclusion: To conclude, all these drugs are potentially useful in the prevention and treatment of diseases. But none of these drugs is a cure-all, specific treatment for COVID-19. Therefore, we must continue to search for an effective drug treatment for this disease until we have a proven successful agent available.

Abstract Even if the symptoms during the acute phase are minimal, COVID-19 not only results in severe respiratory problems but also long-term consequences. Significant long-term consequences are now being identified as neurological and neuropsychiatric problems. The onset of neuropsychiatric symptoms brought on by a lengthy COVID might be challenging to detect and treat in patients with behavioral problems, such as those with autism spectrum disorders (ASD). In this article, we describe three instances of ASD that showed a substantial worsening of neuropsychiatric symptoms after exposure to COVID-19 and subsequent difficulties controlling the post-COVID neuropsychiatric symptoms. The therapy intended to target COVID-19-induced immune reaction was delayed because Case 1 caught SARS-CoV-2 in the early phases of the epidemic. Case 2 had a verified COVID-19 exposure but showed no symptoms during the acute phase, however, she later had severe neuropsychiatric symptoms. Case 3 had a challenging course, in part because of underlying immunological dysregulation and the past use of many immunomodulating drugs. Significant variations in peripheral blood monocytes' generation of inflammatory and counter-regulatory cytokines were seen in cases 1 and 3, for which serial blood samples were taken. The instances discussed here show how COVID-19 has a significant impact on neuropsychiatric symptoms in ASD patients as well as how challenging it is to treat long-term COVID side effects.

Abstract Personalized medicine is the clinical treatment of diseases that is tailored to the physiologic, molecular genetics and lifestyle characteristics of the patient.
Personalized medicine can be considered as a new approach to face diseases and develop traditional methods for their diagnosis and treatment. This novel field of medicine has the potential of changing identification and management of health problems strategies. Corona virus disease 2019 (COVID-19) is an infectious disease that affects the lungs of patients. This novel outbreak was first reported on 31 December 2019 in Wuhan, the capital of Hubei province of China, and it had many effects on people's lives all over the world in various economic, social and health fields until now. Since the start of the pandemic Covid-19, the World Health Organization (WHO) has expressed concern about the public health emergency. Although the disease has mild symptoms and similar to a common cold in most people, in some cases it can lead to pneumonia, acute respiratory distress syndrome, multi-organ dysfunction, and even death. Therefore, due to the different effects of this disease in individuals and even families, the role of personalized medicine becomes more significant and sensitive. Considering the rapid spread and global crisis of Covid-19, recent research has focused more on the control and treatment of the virus. The main goal of this paper is the investigation of different effects of the virus on patients and study of the personalized medicine roles in the control and treatment of the disease.

Abstract The COVID-19 outbreak offers an unmatched chance to take advantage of personalized medicine's benefits for the protection, detection, medication, monitoring, and administration of a fresh public health crisis. Antibiotics, which were formerly regarded as miracle cures and among the most difficult life-saving discoveries of the twentieth century, are now posing a hazard to society as a result of overuse and abuse. Antimicrobial resistance (AMR) is a widespread issue that is becoming worse, and the current COVID-19 pandemic might make things even worse. It has been shown that a significant portion of Covid-19 patients gets secondary microbiological infections. The medical industry is now facing difficulties because of this. As a result, several non-antibiotic techniques have been sought, and their processes have been examined, to slow the spread of AMR.

Abstract Warning of the World Health Organization (WHO) indicates that novel coronavirus (COVID-19) is pandemic and causes global concern. COVID-19 has acute respiratory symptoms which leads to die in many cases through the world. We have found seven variants in 300 patients based on Next Generation Sequencing (NGS) which are related to infectious disease. According to the databases, we confirmed that rs2660 and rs1800450 have association with COVID-19 in the Iranian population.